Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S256000, C546S268100, C546S304000, C514S350000
Reexamination Certificate
active
07999109
ABSTRACT:
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 2997368 (1961-08-01), Barent et al.
patent: 3121103 (1964-02-01), Keller et al.
patent: 3344183 (1967-09-01), Reeder et al.
patent: 3442946 (1969-05-01), Keller et al.
patent: 3534062 (1970-10-01), Wright et al.
patent: 3551427 (1970-12-01), Ott et al.
patent: 3842082 (1974-10-01), Hunziker et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4372975 (1983-02-01), Mouzin et al.
patent: 4954518 (1990-09-01), Takano et al.
patent: 4992091 (1991-02-01), Vinogradoff et al.
patent: 4997940 (1991-03-01), Vinogradoff et al.
patent: 5021591 (1991-06-01), Vinogradoff et al.
patent: 5071468 (1991-12-01), Astles et al.
patent: 5093364 (1992-03-01), Richards et al.
patent: 5155121 (1992-10-01), Niewohner et al.
patent: 5163995 (1992-11-01), Van Heertum et al.
patent: 5185348 (1993-02-01), Niewohner et al.
patent: 5217521 (1993-06-01), Durr
patent: 5217976 (1993-06-01), Ratcliffe et al.
patent: 5236937 (1993-08-01), Bradbury et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5338755 (1994-08-01), Wagon et al.
patent: 5481005 (1996-01-01), Wagon et al.
patent: 5541186 (1996-07-01), Breu et al.
patent: 5571775 (1996-11-01), Van Heertum et al.
patent: 5589478 (1996-12-01), Yamada et al.
patent: 5780488 (1998-07-01), Bergman et al.
patent: 5973148 (1999-10-01), Ringer et al.
patent: 6136971 (2000-10-01), Harrington et al.
patent: 6200995 (2001-03-01), De la Brouse-Elwood et al.
patent: 6297195 (2001-10-01), Gesing et al.
patent: 6297239 (2001-10-01), deSolms et al.
patent: 6316450 (2001-11-01), Bromidge et al.
patent: 6403607 (2002-06-01), Hidaka et al.
patent: 6432624 (2002-08-01), Kikuchi et al.
patent: 6653332 (2003-11-01), Jaen et al.
patent: 6770648 (2004-08-01), McGee et al.
patent: 6939885 (2005-09-01), Ungashe et al.
patent: 7238717 (2007-07-01), Fleming et al.
patent: 7282502 (2007-10-01), Fleming et al.
patent: 7582661 (2009-09-01), Ugashe et al.
patent: 2002/0009116 (2002-01-01), Kobayashi et al.
patent: 2002/0012680 (2002-01-01), Patel et al.
patent: 2002/0013314 (2002-01-01), Zhu et al.
patent: 2002/0037905 (2002-03-01), Dahl et al.
patent: 2002/0037928 (2002-03-01), Jaen et al.
patent: 2002/0052363 (2002-05-01), Dinsmore et al.
patent: 2002/0065303 (2002-05-01), Zhu et al.
patent: 2002/0072530 (2002-06-01), Zhu et al.
patent: 2002/0103202 (2002-08-01), Pinto et al.
patent: 2003/0060460 (2003-03-01), Ohuchida et al.
patent: 2003/0139390 (2003-07-01), McGee et al.
patent: 2004/0167113 (2004-08-01), Ugashe et al.
patent: 2004/0171654 (2004-09-01), Ugashe et al.
patent: 2005/0137193 (2005-06-01), Ungashe et al.
patent: 561703 (1975-03-01), None
patent: 585222 (1977-01-01), None
patent: 2022187 (1970-11-01), None
patent: 2257443 (1973-05-01), None
patent: 3544409 (1986-10-01), None
patent: 3825041 (1990-02-01), None
patent: 0015214 (1980-09-01), None
patent: 0526348 (1993-02-01), None
patent: 0556673 (1993-08-01), None
patent: 0613894 (1994-09-01), None
patent: 884847 (1961-12-01), None
patent: 1332697 (1973-10-01), None
patent: 4364168 (1992-12-01), None
patent: 6-113060 (1994-04-01), None
patent: 145145 (1994-05-01), None
patent: 2001-89412 (2001-04-01), None
patent: WO 93/03013 (1993-02-01), None
patent: WO 94/20142 (1994-09-01), None
patent: WO 95/33462 (1995-12-01), None
patent: WO 96/08483 (1996-03-01), None
patent: WO 97/28129 (1997-08-01), None
patent: WO 98/11218 (1998-03-01), None
patent: WO 98/28270 (1998-07-01), None
patent: WO 98/50029 (1998-11-01), None
patent: WO 99/17777 (1999-04-01), None
patent: WO 99/32433 (1999-07-01), None
patent: WO 99/38845 (1999-08-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 99/55324 (1999-11-01), None
patent: WO 99/55663 (1999-11-01), None
patent: WO 00/05214 (2000-02-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 01/00579 (2001-01-01), None
patent: WO 01/09097 (2001-02-01), None
patent: WO 01/17971 (2001-03-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/19798 (2001-03-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 01/56607 (2001-08-01), None
patent: WO 01/56989 (2001-08-01), None
patent: WO 01/57003 (2001-08-01), None
patent: WO 01/57020 (2001-08-01), None
patent: WO 01/60319 (2001-08-01), None
patent: WO 01/60369 (2001-08-01), None
patent: WO 02/00633 (2002-01-01), None
patent: WO 02/18326 (2002-03-01), None
patent: WO 02/30358 (2002-04-01), None
patent: WO 02/054867 (2002-07-01), None
patent: WO 02/055501 (2002-07-01), None
patent: WO 02/059080 (2002-08-01), None
patent: WO 03/099773 (2003-12-01), None
patent: WO 2004/046092 (2004-06-01), None
patent: WO 2004/058164 (2004-07-01), None
patent: WO 2004/085384 (2004-10-01), None
patent: WO 2004/099127 (2004-11-01), None
patent: WO 2005/004810 (2005-01-01), None
patent: WO 2005/112925 (2005-12-01), None
patent: WO 2006/076644 (2006-07-01), None
patent: WO 2007/014054 (2007-02-01), None
Campbell, Daniel J. et al., “Rapid Acquisition of Tissue-specific Homing Phenotypes by CD4+T Cells Activated in Cutaneous or Mucosal Lymphoid Tissues,”Journal of Experimental Medicine, vol. 195, (Jan. 7, 2002), pp. 135-141.
Dahinden, Clemens, A. et al., “Monocyte Chemotactic Protein 3 Is a Most Effective Basophil- and Eosinophil-activating Chemokine,”Journal of Experimental Medicine, vol. 179, (Feb. 1994), pp. 751-756.
Dannhardt, Gerd et al., “COX-1/COX-2 Inhibitors Based on the Methanone Moiety,”European Journal of Medicinal Chemistry, vol. 37, (2002), pp. 147-161.
Davidson, Natalie J. et al., “T Helper Cell 1-type CD4+T Cells, but Not B Cells, Mediate Colitis in Interleukin 10-deficient Mice,”Journal of Experimental Medicine, vol. 184, (Jul. 1996), pp. 241-251.
Kavanaugh, Arthur F. et al., “Role of CD11/CD18 in Adhesion and Transendothelial Migration of T Cells,” Journal of Immunology, vol. 146, (Jun. 15, 1991), pp. 4149-4156.
Kontoyiannis, Dimitris et al., “Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements: Implications for Joint and Gut-Associated Immunopathologies,”Immunity, vol. 10, (Mar. 1999), pp. 387-398.
Kosiewicz, Michele M. et al., “Th1-Type Responses Mediate Spontaneous Ileitis in a Novel Murine Model of Crohn's Disease,”Journal of Clinical Investigation, vol. 107, No. 6, (Mar. 2001), pp. 695-702.
Kunkel, Eric J. et al., “Lymphocyte CC Chemokine Receptor 9 and Epithelial Thymus-expressed Chemokine (TECK) Expression Distinguish the Small Intestinal Immune Compartment: Epithelial Expression of Tissue-specific Chemokines as an Organizing Principle in Regional Immunity,”Journal of Experimental Medicine, vol. 192, No. 5, (Sep. 4, 2000), pp. 761-767.
Lothrop, Warren C. et al., “Fluorenone-2,3-dicarboxylic Acid and its Anhydride,”Journal of the American Chemical Society, CODEN:JACSAT, vol. 63, (Oct. 1941), pp. 2564-2567.
Murphy, Philip M., “The Molecular Biology of Leukocyte Chemoattractant Receptors,”Annual Review of Immunology, vol. 12, (1994), pp. 593-633.
Neote, Kuldeep et al. “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor,”Cell, vol. 72, (Feb. 12, 1993), pp. 415-425.
Panwala, Chetan M. et al., “A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdrla, Spontaneously Develop Colitis,”Journal of Immunology., vol. 161 ,(1998), pp. 5733-5744.
Papadakis, Konstantinos A. et al. “The Role of thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System,”Journal of Immunology, vol. 165, (2000), pp. 506
Chen B. Shaowu
Fleming Paul E.
Harriman Geraldine C. B.
Shi Zhan
Balasubramanian Venkataraman
Millennium Pharmaceuticals Inc.
LandOfFree
CCR9 inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR9 inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR9 inhibitors and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781755